Executive summary
A Clinical Development Plan (CDP) is one of the most important strategic tools available to biotech and pharmaceutical sponsors. It is intended to provide a clear roadmap from early development through key value inflection points, aligning clinical evidence generation, regulatory strategy, operational execution, and capital deployment.
Yet in practice, many CDPs fail to deliver their intended value.
Some become static internal documents that are rarely revisited. Others are built around idealised timelines, disconnected from operational reality. In many cases, development plans are scientifically robust but commercially or operationally fragile.
As development environments become more complex in 2026, sponsors face growing pressure to demonstrate progress efficiently while preserving capital. Under these conditions, the quality of planning matters more than ever.
This paper explores the common reasons Clinical Development Plans fall short, and how sponsors can create plans that are practical, adaptive, and executable.
The Purpose of a Clinical Development Plan
At its best, a CDP provides more than a summary of intended studies. A well-developed CDP also helps sponsors anticipate risk early and evaluate alternative development pathways before delays become costly.
It should define how a programme will generate the evidence required to achieve regulatory approval, clinical differentiation, and commercial value creation. Projections of timelines and costs also provide a stronger foundation for informed investment and portfolio decisions.
A robust CDP typically aligns:
- Target product profile objectives, unmet medical needs, future market access considerations, and competitive landscape analysis
- Regulatory strategy across target markets
- Clinical study sequencing and milestone planning from preclinical through later-phase development
- Key decision points and go/no-go criteria
- Budget and resourcing assumptions
- Operational dependencies
- Investor value inflection points
Typical Clinical Development Plan Structure
| CDP Section | Typical Contents |
|---|---|
| Target Product Profile | Indication, differentiation, patient population, commercial objectives |
| Regulatory Strategy | FDA/EMA pathway, orphan designation, accelerated routes |
| Clinical Strategy | Phase I–III sequencing, endpoints, biomarkers |
| Operational Feasibility | Country strategy, recruitment assumptions, site capacity |
| CMC / IMP Planning | Manufacturing readiness, IMPD timing, supply strategy |
| Budget & Milestones | Development costs, financing needs, value inflection points |
| Risk Management | Critical path risks and mitigation planning |
Table 1. Illustrative Example: Typical Clinical Development Plan Structure
When Planning Becomes Theoretical
One of the most common weaknesses in CDPs is over-reliance on theoretical assumptions. Timelines may assume rapid site activation, smooth recruitment, immediate manufacturing readiness, or uninterrupted regulatory progress. While possible, these assumptions often reflect best-case conditions rather than likely operating environments.
The result is predictable: milestones begin to slip early, confidence erodes, and management teams are forced into repeated replanning exercises. A CDP should not describe what is possible under perfect conditions. It should describe the most credible route to success under real-world conditions.
Operational Reality Is Often Missing
Many development plans are created primarily through scientific, medical, or regulatory lenses. These are essential inputs, but execution risk is frequently underweighted.
Common examples include:
- Underestimating country start-up timelines
- Overestimating site capacity
- Assuming broad patient availability
- Delayed IMP readiness
- Insufficient vendor integration planning
- Unrealistic
- Limited consideration of standard of care and competing treatment options
These issues do not usually emerge at planning stage. They surface later, when correction becomes expensive. Strong CDPs integrate operational feasibility early, not after strategic decisions have already been made.
Capital Efficiency Depends on Better Planning
For emerging biotech companies, development planning is inseparable from financing strategy. Every delay impacts runway. Every avoidable amendment consumes capital. Every missed milestone may affect valuation or fundraising timing.
A practical CDP helps sponsors deploy resources more effectively by identifying:
- Which studies are essential now
- Which activities can run in parallel
- Where decision gates should sit
- Where external spend should be prioritised
- Which milestones are most value-accretive
In this sense, a CDP is not only a scientific roadmap. It is also a capital allocation framework.
The Best Clinical Development Plans Are Adaptive
Clinical development rarely progresses in a straight line.
New safety data may emerge. Regulators may request additional evidence. Competitors may shift standards of care. Recruitment assumptions may prove inaccurate. For this reason, effective CDPs are living frameworks rather than static documents.
Sponsors should revisit plans regularly based on:
- Emerging clinical data
- Regulatory feedback
- Competitive developments
- Financing environment
- Delivery performance versus assumptions
The strongest programmes are not those that never change course. They are those designed to adapt intelligently.
Cross-Functional Alignment Is Critical
A CDP often fails when different stakeholders interpret it differently. Clinical teams may prioritise scientific ambition. Finance teams may prioritise runway. Investors may focus on catalysts. Operations teams may focus on deliverability.
Unless these perspectives are aligned early, friction emerges later through delays, redesign, or internal conflict. A well-built CDP creates a shared decision-making framework across executive leadership, clinical development, regulatory affairs, CMC, finance, investors / board stakeholders, and external partners.
Translating Strategy Into Delivery
The true value of a CDP is only realised when studies start on time, recruit effectively, and generate usable data. That requires translating strategic intent into executable delivery plans.
This includes:
- In-time organisation of IMP/placebo manufacturing, QP release, and IMPD readiness
- Availability of biomarkers and validated laboratory assays
- Realistic country strategy
- Fit-for-purpose site selection
- Recruitment planning based on evidence
- Operationally efficient protocol design considering patient burden
- Vendor governance
- Clear ownership of critical path activities
Without this bridge between planning and delivery, even strong strategic plans can underperform.
The FGK Perspective
FGK Clinical Research works with biotech and pharmaceutical sponsors who need development plans grounded in execution reality.
Our experience across European and international clinical trial delivery enables us to support sponsors not only in designing programmes, but in stress-testing assumptions before they become delays.
We help clients evaluate:
- Feasible timelines versus optimistic timelines
- Country and site strategy practicality
- Study sequencing dependencies
- Operational impact of protocol design
- Transition from planning into delivery
For many sponsors, especially lean biotech teams, this practical perspective can materially improve predictability, capital efficiency, and speed to milestone achievement.
Looking for a grounded partner for your next clinical program?
TAKE HOME MESSAGE
Clinical Development Plans remain essential, but their value depends entirely on quality and realism.
The most successful plans combine scientific ambition with operational discipline, financial awareness, and the flexibility to adapt as evidence evolves.
In today’s environment, better planning is not bureaucracy. It is competitive advantage.
About the Author:
Mark Thomas
Managing Director FGK UK
Mark is the founder and Managing Director of Clinicology Ltd, a specialized Contract Research Organization (CRO) based in Guildford, UK, which was acquired by FGK Clinical Research in 2024. Before founding Clinicology, he was founding director and board member of a medium sized global CRO. Mark has over 30 years of experience in managing pharmaceutical and medical device studies.